StrainX Bioworks has secured $13 million (approximately ₹124 crore) in a fresh funding round aimed at accelerating large-scale production of alternative proteins through synthetic biology and precision fermentation technologies.
The investment round was led by Prime Venture Partners and Leo Capital, with participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dholakia Ventures, and WindT Angels, a network founded by IIT Delhi alumni.
The newly raised capital will primarily be used to expand the company’s bio-manufacturing fermentation facility in Bhopal and initiate commercial-scale production operations. The startup also plans to strengthen its Bengaluru-based research and development laboratory by hiring additional scientists and upgrading its technological capabilities.
Founded in 2023 by IIT Delhi alumni Akshay Mittal and Alok Malaviya, the company focuses on manufacturing alternative proteins using engineered microbial systems. These proteins are developed in laboratory environments and are designed for applications across food, nutrition, cosmetics, and advanced materials industries.
Alternative proteins are produced from non-animal sources and are increasingly being explored as sustainable substitutes within global food and biotech ecosystems. StrainX combines synthetic biology and precision fermentation to engineer microorganisms such as bacteria, yeast, and fungal cells capable of producing targeted protein outputs at industrial scale.
While synthetic biology enables the modification of microbial systems for specific biological functions, precision fermentation allows these engineered organisms to operate in controlled environments for scalable manufacturing processes.
The startup stated that it has already received approval in the United States to commercialise its products and is now working toward securing regulatory approvals in India. Currently, StrainX operates a 10,000-litre fermentation facility in Bhopal, with plans to increase capacity nearly tenfold over the next two years.
According to Mittal, the company’s India-focused manufacturing model gives it a competitive pricing advantage in the global market. Product pricing varies based on purity levels, packaging specifications, application areas, and production scale, ranging from hundreds to thousands of dollars per kilogram.
The development comes as India’s biotechnology sector continues to expand rapidly. With more than 11,000 biotech startups operating across the country, India’s bioeconomy is projected to emerge as a $300 billion market opportunity by 2030, driven by growing investments in biotechnology, food innovation, sustainable manufacturing, and life sciences research.
